112 related articles for article (PubMed ID: 15347137)
1. The relative orientation of the Arg and Asp side chains defined by a pseudodihedral angle as a key criterion for evaluating the structure-activity relationship of RGD peptides.
Kostidis S; Stavrakoudis A; Biris N; Tsoukatos D; Sakarellos C; Tsikaris V
J Pept Sci; 2004 Aug; 10(8):494-509. PubMed ID: 15347137
[TBL] [Abstract][Full Text] [Related]
2. A three-residue cyclic scaffold of non-RGD containing peptide analogues as platelet aggregation inhibitors: design, synthesis, and structure--function relationships.
Stavrakoudis A; Bizos G; Eleftheriadis D; Kouki A; Panou-Pomonis E; Sakarellos-Daitsiotis M; Sakarellos C; Tsoukatos D; Tsikaris V
Biopolymers; 2000-2001; 56(1):20-6. PubMed ID: 11582574
[TBL] [Abstract][Full Text] [Related]
3. Structure and function of RGD peptides derived from disintegrin proteins.
Kim J; Hong SY; Park HS; Kim DS; Lee W
Mol Cells; 2005 Apr; 19(2):205-11. PubMed ID: 15879703
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore refinement of gpIIb/IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides.
Müller G; Gurrath M; Kessler H
J Comput Aided Mol Des; 1994 Dec; 8(6):709-30. PubMed ID: 7738606
[TBL] [Abstract][Full Text] [Related]
5. Correlation of molecular shape with GPIIb-IIIa receptor antagonist activity in RGD peptides.
Tung JS; Jakubowski JA; Heath WF; Utterback BG; Herron DK
Receptor; 1993; 3(4):343-56. PubMed ID: 8142908
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of RGD peptides involved in bone biology.
Schaffner P; Dard MM
Cell Mol Life Sci; 2003 Jan; 60(1):119-32. PubMed ID: 12613662
[TBL] [Abstract][Full Text] [Related]
7. Solution structure of a cyclic RGD peptide that inhibits platelet aggregation.
Jois SD; Tambunan US; Chakrabarti S; Siahaan TJ
J Biomol Struct Dyn; 1996 Aug; 14(1):1-11. PubMed ID: 8877556
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
[TBL] [Abstract][Full Text] [Related]
9. Disintegrins: RGD-containing proteins which inhibit cell/matrix interactions (adhesion) and cell/cell interactions (aggregation) via the integrin receptors.
Williams JA
Pathol Biol (Paris); 1992 Oct; 40(8):813-21. PubMed ID: 1484742
[TBL] [Abstract][Full Text] [Related]
10. Cyclic RGD peptidomimetics containing bifunctional diketopiperazine scaffolds as new potent integrin ligands.
Marchini M; Mingozzi M; Colombo R; Guzzetti I; Belvisi L; Vasile F; Potenza D; Piarulli U; Arosio D; Gennari C
Chemistry; 2012 May; 18(20):6195-207. PubMed ID: 22517378
[TBL] [Abstract][Full Text] [Related]
11. Calpha-H...O = C hydrogen bonds contribute to the specificity of RGD cell-adhesion interactions.
Bella J; Humphries MJ
BMC Struct Biol; 2005 Feb; 5():4. PubMed ID: 15710040
[TBL] [Abstract][Full Text] [Related]
12. Solution structure of gamma-bungarotoxin: the functional significance of amino acid residues flanking the RGD motif in integrin binding.
Shiu JH; Chen CY; Chang LS; Chen YC; Chen YC; Lo YH; Liu YC; Chuang WJ
Proteins; 2004 Dec; 57(4):839-49. PubMed ID: 15390258
[TBL] [Abstract][Full Text] [Related]
13. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis of integrin recognition and the inhibition of integrin-mediated cell functions by novel nonpeptidic surrogates of the Arg-Gly-Asp sequence.
Greenspoon N; Hershkoviz R; Alon R; Varon D; Shenkman B; Marx G; Federman S; Kapustina G; Lider O
Biochemistry; 1993 Feb; 32(4):1001-8. PubMed ID: 8093840
[TBL] [Abstract][Full Text] [Related]
15. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins.
Pfaff M; Tangemann K; Müller B; Gurrath M; Müller G; Kessler H; Timpl R; Engel J
J Biol Chem; 1994 Aug; 269(32):20233-8. PubMed ID: 8051114
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressory activity of the cyclodimeric peptide with RGD-sequences.
Szewczuk Z; Buczek P; Stefanowicz P; Krajewski K; Wieczorek Z; Siemion IZ
Acta Biochim Pol; 2001; 48(1):121-30. PubMed ID: 11440161
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of cyclic oligopeptides containing an Arg-Gly-Asp (RGD) sequence.
Sofuku S; Hoshida A; Shimada T; Takada Y; Takakuwa T
Chem Pharm Bull (Tokyo); 1999 Dec; 47(12):1799-801. PubMed ID: 10748723
[TBL] [Abstract][Full Text] [Related]
18. Investigation of conformational specificity at GPIIb/IIIa: evaluation of conformationally constrained RGD peptides.
Peishoff CE; Ali FE; Bean JW; Calvo R; D'Ambrosio CA; Eggleston DS; Hwang SM; Kline TP; Koster PF; Nichols A
J Med Chem; 1992 Oct; 35(21):3962-9. PubMed ID: 1433203
[TBL] [Abstract][Full Text] [Related]
19. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides.
Gurrath M; Müller G; Kessler H; Aumailley M; Timpl R
Eur J Biochem; 1992 Dec; 210(3):911-21. PubMed ID: 1483474
[TBL] [Abstract][Full Text] [Related]
20. Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial biological studies.
Pearson DA; Lister-James ; McBride WJ; Wilson DM; Martel LJ; Civitello ER; Dean RT
J Med Chem; 1996 Mar; 39(7):1372-82. PubMed ID: 8691467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
